Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Large Decrease in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a large decline in short interest in the month of May. As of May 29th, there was short interest totaling 1,948 shares, a decline of 89.5% from the May 14th total of 18,505 shares. Based on an average trading volume of 324,828 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s shares are sold short.

Provectus Biopharmaceuticals Price Performance

PVCT traded up $0.00 during trading hours on Tuesday, reaching $0.07. 10,090 shares of the company’s stock traded hands, compared to its average volume of 144,624. The firm has a 50-day moving average price of $0.06 and a 200 day moving average price of $0.06. Provectus Biopharmaceuticals has a 52-week low of $0.04 and a 52-week high of $0.11.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.